Ginette 35 Contraceptive Pill

Ginette 35 Contraceptive Pill (Cyproterone Acetate and Ethinylestradiol Tablets) - Product Information

Ginette 35 (Cyproterone Acetate and Ethinylestradiol Tablets) is indicated as an Oral contraception in women requiring treatment for androgen-dependent diseases such as acne,seborrhea, alopecia and mild forms of hirsutism.
However, Ginette 35 is not recommended in women solely for contraception. It should not be used in combination with other hormonal contraceptives. Ginette 35 is also indicated for the relief of symptoms of polycystic ovary syndrome.
We also have in stock Yasmin Birth Control Pills (Drospirenone and Ethinyl Estradiol Contraceptive Tablets) which are also used to treat the same indications.

Name of the Drug

Ginette-35 Contraceptive Tablets.

Manufacturer of Ginette-35 Contraceptive Tablets

Cipla Limited, India 
Website: www.cipla.com

Active Pharmaceutical Ingredients

The active ingredients present in Ginette-35 Contraceptive tablets are Cyproterone Acetate, and Ethinyl Estradiol (Ethinylestradiol or Ethinyl Oestradiol). Each film-coated Ginette 35 tablet contains: 2 mg of Cyproterone Acetate and 0.035 mg (35 micrograms) of Ethinylestradiol (Ethinyl Oestradiol).

Uses of Ginette-35 Contraceptive Pill

Ginette-35 Contraceptive Pill (Generic Cyproterone Acetate and Ethinylestradiol Tablets) is indicated for the treatment of women with severe acne, with associated symptoms of androgenization, including seborrhea and mild hirsutism. Novo-Cyproterone / Ethinyl Estradiol Tablets should be used only when acne is unresponsive to topical therapy and oral antibiotic treatments. Ginette-35 Contraceptive Pill should not be prescribed for the purpose of contraception alone. However, when taken as recommended Cyproterone Acetate and Ethinylestradiol Tablets will provide reliable contraception in patients treated for the above clinical conditions.

Ginette-35 Contraceptive Pills - Dosage

Generic Cyproterone Acetate and Ethinylestradiol tablets should be administered exactly as suggested by your doctor.
Ginette 35 inhibits ovulation and, thereby, prevents conception. Patients who are using Ginette-35 should not, therefore, use an additional hormonal contraceptive, as this will expose the patient to an excessive dose of hormones and is not necessary for effective contraception.
First Treatment course One tablet daily for 21 days following the arrows, starting on the first day of the menstrual cycle (the first day of menstruation counting as day 1).
Subsequent Courses: Each subsequent course is started after 7 tablet-free days have followed the preceding course.
When the contraceptive action of Ginette-35 is also to be employed, it is essential that the above instructions be rigidly adhered to. Should bleeding fail to occur during the tablet-free interval, the possibility of pregnancy must be excluded before the next pack is started.

Ginette 35 tablets work effectively if the amount of is maintained at a constant level in the body. You should be systematic about the daily schedule for the medication such that you take Ginette 35 tablets at about the same time every day, to get the maximum benefit of the medication. Continue taking tablets without missing any doses for the recommended treatment period.

Please consult your doctor for exact dosing instructions. Ginette-35 tablets (Generic Cyproterone Acetate and Ethinylestradiol tablets) should be administered in the dose prescribed by the doctor and for the duration recommended by the doctor.

Missed Dose

A single delayed tablet should be taken as soon as possible, and if this can be done within 12 hours of the correct time, contraceptive protection is maintained. With longer delays, additional contraception is needed.
Only the most recently delayed tablet should be taken, earlier missed tablets being omitted, and additional non-hormonal methods of contraception (except the rhythm or temperature methods) should be used for the next 7 days, while the next 7 tablets are being taken.
Additionally, therefore, if tablet(s) have been missed during the last 7 days of a pack, there should be no break before the next pack is started. In this situation, a withdrawal bleed should not be expected until the end of the second pack. Some breakthrough bleeding may occur on the days a tablet is taken, but this is not clinically significant. If the patient does not have a withdrawal bleed during the tablet-free interval following the end of the second pack, the possibility of pregnancy must be ruled out before starting the next pack.

Mechanism of Action

Cyproterone Acetate is a competitive antagonist on the androgen receptor, has inhibitory effects on the androgen-synthesis in target cells and produces a decrease on the androgen blood concentration through an anti-gonadotropic effect.
This anti-gonadotropic effect is amplified by ethinylestradiol which also up-regulates the synthesis of Sex-Hormone-Binding Globulin (SHBG) in plasma. By this mechanism, it reduces free, biologically available androgen in the circulation.

Storage Instructions for Ginette 35 Contraceptive Pill (Cyproterone Acetate and Ethinylestradiol Tablets)

Store Ginette 35 Contraceptive Pill (Cyproterone Acetate and Ethinylestradiol Tablets) at controlled room temperature (20°C to 25°C),protected from heat, moisture, and sunlight. Excursions are permitted from 15°C to 30°C.
Retain the original packing of the medication and do not consume past its expiration date printed on the blister pack. Keep the pack of Cyproterone Acetate and Ethinylestradiol Tablets away from the reach of children and pets. Do not dispose Ginette 35 Contraceptive Pill along with domestic waste or sewage. Consult your doctor or pharmacist about the correct method of disposal.

Contraindications

Ginette 35 Contraceptive tablets are contraindicated in patients with a hypersensitivity to Cyproterone Acetate, Ethinylestradiol or any inactive ingredient present in tablets. Ginette 35 Contraceptive tablets are also contraindicated in the following cases:

• History of or actual thrombophlebitis or thromboembolic disorders
• History of or actual cerebrovascular disorders
• History of or actual myocardial infarction or coronary arterial disease
• Active liver disease
• Previous or existing liver tumours (benign or malignant)
• History of cholestatic jaundice
• Known or suspected carcinoma of the breast
• Known or suspected estrogen-dependent neoplasia
• Undiagnosed abnormal vaginal bleeding
• Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields
• Concomitant use with other estrogen/progestogen combinations or estrogens or progestogens alone
• When pregnancy is suspected or diagnosed
• Severe diabetes with vascular changes
• A history of otosclerosis with deterioration during pregnancy

Overdose

There have been no reports of serious deleterious effects from overdose.Symptoms that may occur in case of taking an overdose of Ginette-35 Contraceptive tablets are: nausea, vomiting and withdrawal bleeding. Withdrawal bleeding may even occur in girls before their menarche, if they have accidentally taken Ginette-35. There are no antidotes and further treatment should be symptomatic.

Warnings and Precautions

Circulatory Disorders
An increased risk of venous and arterial thrombotic and thromboembolic diseases such as stroke, myocardial infarction, pulmonary thrombosis, and deep venous embolism have been associated with the use of COCs, according to epidemiology research. These events occur rarely.
Tumours
There is a slightly increased relative risk of diagnosing breast cancer in women who are currently using COCs. This was reported in a meta-analysis from 54 epidemiological studies. During the course of ten years post cessation of COC, the risk of diagnosing breast cancer gradually disappears. The excess number of breast cancer diagnoses in current and recent COC users is small compared to the risk of breast cancer overall as breast cancer is rare in women under 40 years of age.
Hypertension:
Many women taking COCs have had small increases in blood pressure reported, however clinically relevant increases are rare. The doctor should advise withdrawal of the COC if a sustained clinically significant hypertension develops during the COC use and the hypertension should be treated.
Hypertriglyceridemia and pancreatitis:
Women using COCs may be at risk of pancreatitis if they have hypertriglyceridemia, or a family history of hypertriglyceridemia.
Pregnancy:
Jaundice and/or pruritus related to gallstone formation; cholestasis; systemic lupus erythematosus; porphyria; Sydenham's chorea; haemolytic uraemic syndrome; herpes gestationis; otosclerosis-related hearing loss have been reported to occur or deteriorate with both pregnancy and COC use. The evidence of an association with COC use is inconclusive.
Liver function:
Disturbances of liver function (acute or chronic) may indicate COC use discontinuation until liver function returns to normal (as assessed via liver function markers). Recurrence of cholestatic jaundice which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of COCs.
Diabetes:
Diabetic women should be carefully monitored while taking COCs as COCs may have an effect on peripheral insulin resistance and glucose tolerance. However, there is no evidence for a need to alter the therapeutic regimen in diabetes using COCs.
Bleeding Irregularities:
Withdrawal bleeding may not occur during the interval where the white inactive pills are being taken, or during the tablet free interval, in some women. It is unlikely that the woman is pregnant if the suggested directions for taking the COC have been followed. If two withdrawal bleeds are missed or if the COC has not been taken according to these directions prior to the first missed withdrawal bleeding, p regnancy must be ruled out before COC use is continued.
Crohn's disease:
Has been associated with COC use.
Ulcerative colitis:
Has been associated with COC use.
Chloasma:
Women should avoid exposure to the sun or ultraviolet radiation whilst taking COCs if they have a tendency to chloasma. Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum.
Hirsutism:
If symptoms have recently developed or increased substantially in women suffering from hirsutism, the causes (androgen-producing tumor, adrenal enzyme defect) must be clarified by differential diagnosis.
Hepatitis C:
During clinical trials with the combination drug regimen ombitasvir / paritaprevir / ritonavir and dasabuvir with and without ribavirin, transient, asymptomatic elevations of alanine transaminase (ALT) greater than 5 times the upper limit of normal (ULN) were significantly more frequent in women using ethinyloestradiol-containing medications such as combined oral contraceptives, contraceptive patches, or contraceptive vaginal rings.

Side Effects of Ginette 35 contraceptive Pills

The most commonly reported side effects with Ginette 35 contraceptive pills (Cyproterone Acetate and Ethinylestradiol Tablets) are nausea, abdominal pain, increased weight, headache, depressed mood, altered mood, breast pain, breast tenderness. They occur in 1 % or more of users.
There is an increased risk of thromboembolism for all women who use Cyproterone Acetate and Ethinylestradiol Tablets.

Cyproterone Acetate Ethinylestradiol Tablets During Pregnancy

Cyproterone Acetate Ethinylestradiol Tablets (Ginette 35) has been classified by the US FDA as Pregnancy Category X.
Cyproterone Acetate snd Ethinylestradiol Tablets are is not indicated during pregnancy. If pregnancy occurs during treatment with Ginette 35, further intake must be stopped.
Animal studies have revealed that feminisation of male foetuses may occur if cyproterone acetate is administered during the phase of embryogenesis at which differentiation of the external genitalia occurs.
Although the results of these tests are not necessarily relevant to man, the possibility must be considered that administration of the product to women after the 45th day of pregnancy could cause feminisation of male foetuses. It follows from this that pregnancy is an absolute contraindication for treatment with Ginette 35, and must be excluded before such treatment is started.
Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Cyproterone Acetate Ethinylestradiol Tablets (Ginette 35) Nursing Considerations

The use of Cyproterone Acetate Ethinylestradiol tablets during lactation may lead to a reduction in the volume of milk produced and to a change in its composition. Minute amounts of the active substances are excreted with the milk. These amounts may affect the child particularly in the first 6 weeks postpartum. Mothers who are breastfeeding should be advised not to take Cyproterone Acetate Ethinylestradiol tablets until the nursing mother has weaned her child off breast milk.
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets (Ginette 35 Pills) Online From Only $1.15 per Pill

You can buy Cyproterone Acetate 2 mg Ethinylestradiol 35 microgram Tablets online from Everest Online Pharmacy at a cheap price. Ginette-35 Contraceptive pills, manufactured by Cipla Limited, India, are supplied in a blister strip of 21 tablets. The tablets cost only $1.15 per unit when you place an order for 252 tablets.

Disclaimer

The above information is provided to the best of our knowledge and in good faith. It is without a warrant of any kind, expressed or implied.

Shipping Restriction